Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
NASH Drug Development: Seeing the Light at the End of the Tunnel?
J Clin Transl Hepatol
(Unknown)
Published: 2023
Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis.
Adhoute X; Pietri O; Pénaranda G; Wolf T; Beaurain P; Monnet O; Laquière A; Bonomini J; Neumann F; Levrel O; Buono JP; Hanna X; Castellani P; Perrier H; Bourliere M; Anty R.
J Clin Transl Hepatol
(Unknown)
Published: 2023
Serum Soluble Vascular Endothelial Growth Factor Receptor 1 as a Potential Biomarker of Hepatopulmonary Syndrome.
Li YJ; Wu XF; Wang DD; Li P; Liang H; Hu XY; Gan JQ; Sun YZ; Li JH; Li J; Shu X; Song AL; Yang CY; Yang ZY; Yu WF; Yang LQ; Wang XB; Belguise K; Xia ZY; Yi B.
J Clin Transl Hepatol
(Unknown)
Published: 2023
Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease.
Huang JF; Tsai PC; Yeh ML; Huang CF; Huang CI; Lee MH; Hsu PY; Wang CW; Wei YJ; Liang PC; Lin YH; Hsieh MH; Yang JF; Hsieh MY; Jang TY; Bair MJ; Lin ZY; Dai CY; Yu ML; Chuang WL.
J Clin Transl Hepatol
(Unknown)
Published: 2023
Secondary Iron Overload and the Liver: A Comprehensive Review.
J Clin Transl Hepatol
(Unknown)
Published: 2023